Senators endorse NIH budget increase, rebuking Trump cut

The Appropriations Committee retained all 27 NIH institutes and centers, rejecting a White House consolidation plan.

July 31, 2025 Check out STAT+

Sponsored By

STAT+ | Senate committee endorses NIH budget increase, rebuking Trump administration's proposed 40% cut Bipartisan Senate committee says no to deep NIH budget cuts and consolidation proposal from Trump administration By Jonathan Wosen Trump escalates demands that pharma companies lower their drug prices Trump demanded, once again, that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the directive. By Elaine Chen STAT+ | With $1.3 billion in hand, VC firm Frazier remains bullish on biotech Venture capital firm Frazier Life Sciences is one of the few new biotech investment funds raised amid the ongoing market upheaval.  By Allison DeAngelis Alex Hogan/STAT Opinion: Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine It is ironic, or maybe fitting, that Vinay Prasad's downfall seems related to a Sarepta drug, Elevidys, that is neither safe nor effective. By Adam Cifu STAT+ | Moderna lays off 10% of workforce in further cost-cutting move The company, facing government and competitive challenges, said job cuts were necessary in order for it to achieve its budget targets. By Adam Feuerstein Opinion: Medical students must be able to voice ethical concerns during clinical rotations With the current assessment structure, medical students' attention is pulled toward impressing doctors and administrators instead of patients. By Chad Childers ADOBE Opinion: The Vaccine Injury Compensation Program needs to be updated, not eliminated Eliminating the Vaccine Injury Compensation Program would hurt people with valid claims of being harmed by a vaccine. By Dorit R. Reiss and Arthur L. Caplan STAT+ | Are we sure Vinay Prasad's ouster is positive for biotech? It's hard not to see Prasad's exit as a complete and total victory for Sarepta Therapeutics, Adam Feuerstein writes. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser